John Marous
Directeur/Bestuurslid bij Heart Input Output, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Dale Tomrdle | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | - |
William W. Cimino | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | - |
Adam J. Katz | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | 14 jaar |
Utkars Jain | M | - |
Heart Input Output, Inc.
Heart Input Output, Inc. Packaged SoftwareTechnology Services Heart Input Output, Inc. provides cloud-based tool using data from electrocardiograms to develop deep learning algorithms focused on individualized predictions through identifying arterial stenosis. It specializes in beat detection, rhythm analysis, disease detection, and Major Adverse Cardiac Events (MACE) risk analysis. The company is headquartered in Pittsburgh, PA. | - |
J. William Futrell | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | 14 jaar |
Roy J. Bostock | M | 83 |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | - |
Nicholas M. Pachuda | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | - |
Michael Leasure | M | - |
Heart Input Output, Inc.
Heart Input Output, Inc. Packaged SoftwareTechnology Services Heart Input Output, Inc. provides cloud-based tool using data from electrocardiograms to develop deep learning algorithms focused on individualized predictions through identifying arterial stenosis. It specializes in beat detection, rhythm analysis, disease detection, and Major Adverse Cardiac Events (MACE) risk analysis. The company is headquartered in Pittsburgh, PA. | - |
St. John Morgan | M | - |
Gid Bio Inc.
Gid Bio Inc. Medical/Nursing ServicesHealth Services Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 9 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- John Marous
- Persoonlijk netwerk